The medtech industry has hit back at claims Australians are paying inflated prices for medical devices, as an evaluation reveals substantial savings from Prescribed List reforms but says further pricing work remains.
The medtech industry has hit back at claims Australians are paying inflated prices for medical devices, as an evaluation reveals substantial savings from Prescribed List reforms but says further pricing work remains.
This content is for paid subscribers only.
Start your free trial nowor purchase a monthly or annual subscription to read.